Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

  • Technology appraisal guidance
  • TA895
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence